Literature DB >> 31328110

Metastases free thyroid cancer patients harbouring TERT mutations may benefit from a more intensive treatment and follow-up.

Alessandro Antonelli1, Silvia Martina Ferrari1, Giusy Elia1, Armando Patrizio1, Poupak Fallahi2.   

Abstract

Entities:  

Year:  2019        PMID： 31328110      PMCID： PMC6606473          DOI： 10.21037/gs.2019.05.05

Source DB:  PubMed          Journal:  Gland Surg        ISSN： 2227-684X


× No keyword cloud information.
  21 in total

1.  Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.

Authors:  R Michael Tuttle; Hernan Tala; Jatin Shah; Rebecca Leboeuf; Ronald Ghossein; Mithat Gonen; Matvey Brokhin; Gal Omry; James A Fagin; Ashok Shaha
Journal:  Thyroid       Date:  2010-10-29       Impact factor: 6.568

2.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

3.  The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.

Authors:  Tae Yong Kim; Won Bae Kim; Yoon Soo Rhee; Ja Young Song; Jung Min Kim; Gyungyub Gong; Seungkoo Lee; Sang Yoon Kim; Seong Chul Kim; Suck Joon Hong; Young Kee Shong
Journal:  Clin Endocrinol (Oxf)       Date:  2006-09       Impact factor: 3.478

4.  BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.

Authors:  Mingzhao Xing; William H Westra; Ralph P Tufano; Yoram Cohen; Eli Rosenbaum; Kerry J Rhoden; Kathryn A Carson; Vasily Vasko; Alexandr Larin; Giovanni Tallini; Sara Tolaney; Elizabeth H Holt; Pei Hui; Christopher B Umbricht; Shehzad Basaria; Marge Ewertz; Anthony P Tufaro; Joseph A Califano; Matthew D Ringel; Martha A Zeiger; David Sidransky; Paul W Ladenson
Journal:  J Clin Endocrinol Metab       Date:  2005-09-20       Impact factor: 5.958

5.  Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells.

Authors:  Alessandro Antonelli; Silvia Martina Ferrari; Poupak Fallahi; Piero Berti; Gabriele Materazzi; Michele Minuto; Riccardo Giannini; Ivo Marchetti; Lucio Barani; Fulvio Basolo; Ele Ferrannini; Paolo Miccoli
Journal:  Clin Endocrinol (Oxf)       Date:  2008-09-10       Impact factor: 3.478

6.  Role of neck ultrasonography in the follow-up of children operated on for thyroid papillary cancer.

Authors:  Alessandro Antonelli; Paolo Miccoli; Poupak Fallahi; Mariano Grosso; Claudia Nesti; Claudio Spinelli; Ele Ferrannini
Journal:  Thyroid       Date:  2003-05       Impact factor: 6.568

Review 7.  BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.

Authors:  Mingzhao Xing
Journal:  Endocr Rev       Date:  2007-10-16       Impact factor: 19.871

8.  Telomerase: central regulator of all of the hallmarks of cancer.

Authors:  Kee Chung Low; Vinay Tergaonkar
Journal:  Trends Biochem Sci       Date:  2013-08-07       Impact factor: 13.807

9.  Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.

Authors:  Mingzhao Xing; Ali S Alzahrani; Kathryn A Carson; David Viola; Rossella Elisei; Bela Bendlova; Linwah Yip; Caterina Mian; Federica Vianello; R Michael Tuttle; Eyal Robenshtok; James A Fagin; Efisio Puxeddu; Laura Fugazzola; Agnieszka Czarniecka; Barbara Jarzab; Christine J O'Neill; Mark S Sywak; Alfred K Lam; Garcilaso Riesco-Eizaguirre; Pilar Santisteban; Hirotaka Nakayama; Ralph P Tufano; Sara I Pai; Martha A Zeiger; William H Westra; Douglas P Clark; Roderick Clifton-Bligh; David Sidransky; Paul W Ladenson; Vlasta Sykorova
Journal:  JAMA       Date:  2013-04-10       Impact factor: 56.272

10.  TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.

Authors:  Miguel Melo; Adriana Gaspar da Rocha; João Vinagre; Rui Batista; Joana Peixoto; Catarina Tavares; Ricardo Celestino; Ana Almeida; Catarina Salgado; Catarina Eloy; Patrícia Castro; Hugo Prazeres; Jorge Lima; Teresina Amaro; Cláudia Lobo; Maria João Martins; Margarida Moura; Branca Cavaco; Valeriano Leite; José Manuel Cameselle-Teijeiro; Francisco Carrilho; Manuela Carvalheiro; Valdemar Máximo; Manuel Sobrinho-Simões; Paula Soares
Journal:  J Clin Endocrinol Metab       Date:  2014-01-29       Impact factor: 5.958
View more
  2 in total

Review 1.  Novel treatments for anaplastic thyroid carcinoma.

Authors:  Silvia Martina Ferrari; Giusy Elia; Francesca Ragusa; Ilaria Ruffilli; Concettina La Motta; Sabrina Rosaria Paparo; Armando Patrizio; Roberto Vita; Salvatore Benvenga; Gabriele Materazzi; Poupak Fallahi; Alessandro Antonelli
Journal:  Gland Surg       Date:  2020-01

Review 2.  Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer.

Authors:  Dana M Hartl; Joanne Guerlain; Ingrid Breuskin; Julien Hadoux; Eric Baudin; Abir Al Ghuzlan; Marie Terroir-Cassou-Mounat; Livia Lamartina; Sophie Leboulleux
Journal:  Cancers (Basel)       Date:  2020-11-06       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.